Editas Medicine (EDIT) Tops Q2 EPS by 21c, misses on revenue

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.56), $0.21 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $2.89 million versus the consensus estimate of $4.17 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
• Piper Sandler picks Payments and Consumer Finance winners as multiples reset
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations